Fuji Pharma Co.,Ltd.

4554 TSE Pharmaceuticals Pharmaceutical
TSE Prime
¥1,737.00
+0.35%
Delayed · cached 15 min

Fair value analysis

4554
Fuji Pharma Co.,Ltd.
PharmaceuticalsPharmaceutical
¥1,737.00
Close used for this calculation
¥2,264.04Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
62/100
Profitability13/25
Returns15/25
Balance Sheet16/25
Efficiency18/25
Growth14/25
Good
Quality radar
62Prof.13/25Ret.15/25Eff.18/25B.Sht16/25Growth14/25

Consensus fair value

¥2,264.04
Below FV
▲ +30.3% against the close used
Model range ¥459.60 – ¥3,589.40
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥459.60Fair value¥2,264.04Bull¥3,589.40
FairClose
52-week traded range
52W low ¥1,484.0052W high ¥2,526.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Fuji Pharma Co.,Ltd. closed at ¥1,737.00, 23.3% below the consensus fair value of ¥2,264.04 drawn from 9 valuation models.

Financial DNA score 62/100 — Good. P/E of 14.1x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
¥2,525.08
+45.4%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=5.4%, r=10%, tg=3%, n=10yr
Graham Number
¥2,297.83
+32.3%
√(22.5 × EPS × BVPS)
EPS=122.94, BVPS=1908.79
P/E Fair Value
¥2,458.80
+41.6%
EPS × 20x (sector P/E)
EPS=122.94, Sector P/E=20x
Peter Lynch (PEG)
¥662.65
-61.9%
EPS × Growth% (PEG = 1 is fair)
EPS=122.94, g=5.4%
EV/EBITDA
¥3,589.40
+106.6%
(EBITDA × 12.7x − Net Debt) ÷ Shares
EBITDA=8.87B
Dividend Discount (DDM)
¥1,040.40
-40.1%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=45.51, r=10%, g=5.4%
Book Value (P/B)
¥459.60
-73.5%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=1908.79, ROE=6.5%, g=5.4%, r=10%
Reverse DCF
¥1,737.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 2.4% | Historical: 5.4%
Margin of Safety
¥1,820.43
+4.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=2427.24, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.